Quality of life in prostate cancer

European Journal of Cancer

Volumn 41, Issue 6, 2005, Pages 922-931

  Talcott, James A ^a   Clark, Jack A ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BOSTON UNIVERSITY   (United States)

Author keywords

Health related quality of life; Measurements; Prostate cancer; Treatment

Indexed keywords

ANDROGEN; PROSTATE SPECIFIC ANTIGEN; SILDENAFIL;

BRACHYTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; DIARRHEA; ERECTILE DYSFUNCTION; FATIGUE; FOOD AND DRUG ADMINISTRATION; FUNCTIONAL ASSESSMENT; HORMONAL THERAPY; HUMAN; HUMAN RELATION; PRIORITY JOURNAL; PROSTATE CANCER; PSYCHOSOCIAL CARE; QUALITY OF LIFE; QUESTIONNAIRE; RADIATION INJURY; RECTUM DISEASE; RECTUM HEMORRHAGE; REVIEW; SEX ROLE; SEXUAL DYSFUNCTION; TREATMENT OUTCOME; URINARY DYSFUNCTION; URINARY TRACT OBSTRUCTION; URINE INCONTINENCE; WELLBEING;

EID: 16244379234     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2004.12.030     Document Type: Article

References (88)

1. C.R. Pound, A.W. Partin, and M.A. Eisenberger Natural history of progression after PSA elevation following radical prostatectomy JAMA 281 1999 1591 1597
2. D.P. Byar Proceedings: The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate Cancer 32 1973 1126 1130
3. E.D. Crawford, M.A. Eisenberger, and D.G. McLeod A controlled trial of leuprolide with and without flutamide in prostatic carcinoma [published erratum appears in N Engl J Med 1989 Nov 16;321(20):1420] N Engl J Med 321 1989 419 424
4. M.A. Eisenberger, B.A. Blumenstein, and E.D. Crawford Bilateral orchiectomy with or without flutamide for metastatic prostate cancer N Engl J Med 339 1998 1036 1042
5. M.V. Pilepich, R. Caplan, and R.W. Byhardt Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31 J Clin Oncol 15 1997 1013 1021
6. D.A. Loblaw, D.S. Mendelson, and J.A. Talcott American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer J Clin Oncol 22 2004 2927 2941
7. J.A. Talcott Androgen deprivation as primary treatment for early prostate cancer: should we "Just Do Something" J Natl Cancer Inst 94 2002 407 409
8. M.J. Moore, B. O'Sullivan, and I.F. Tannock How expert physicians would wish to be treated if they had genitourinary cancer J Clin Oncol 6 1988 1736 1745
9. F.J. Fowler, M. McNaughton Collins, and P.C. Albertsen Comparison of recommendations by urologists and radiation oncologists for treatment of clinically localized prostate cancer [see comments] JAMA 283 2000 3217 3222
10. N. Mills, J.L. Donovan, and M. Smith Perceptions of equipoise are crucial to trial participation: a qualitative study of men in the ProtecT study Control Clin Trials 24 2003 272 282
11. A.L. Zietman, H. Thakral, and L. Wilson Conservative management of prostate cancer in the prostate specific antigen era: the incidence and time course of subsequent therapy J Urol 166 2001 1702 1706
12. J. Donovan, N. Mills, and M. Smith Quality improvement report: Improving design and conduct of randomised trials by embedding them in qualitative research: ProtecT (prostate testing for cancer and treatment) study. Commentary: presenting unbiased information to patients can be difficult BMJ 325 2002 766 770
13. C.A. Carter, T. Donahue, and L. Sun Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era J Clin Oncol 21 2003 4001 4008
14. I.M. Thompson, P.J. Goodman, and C.M. Tangen The influence of finasteride on the development of prostate cancer N Engl J Med 349 2003 215 224
15. M.D. Michaelson, J.A. Talcott, and M.R. Smith Prostate cancer: metastatic Clin Evid 2002 881 890
16. P.K. Pietrow, D.J. Parekh, and J.A. Smith Health related quality of life assessment after radical prostatectomy in men with prostate specific antigen only recurrence J Urol 166 2001 2286 2290
17. I.F. Tannock, D. Osoba, and M.R. Stockler Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points J Clin Oncol 14 1996 1756 1764
18. I. Tannock, M. Gospodarowicz, and W. Meakin Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response J Clin Oncol 7 1989 590 597
19. I.F. Tannock False-positive results in clinical trials: multiple significance tests and the problem of unreported comparisons J Natl Cancer Inst 88 1996 206 207
20. C.A. McHorney, J.E. Ware, and A.E. Raczek The MOS36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs Med Care 31 1993 247 263
21. D.M. McNair, M. Lorr, and L.F. Droppleman Profile of Mood States 2nd ed. 1981 Educational and Industrial Testing Service San Diego
22. N.K. Aaronson, S. Ahmedzai, and B. Bergman The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology J Natl Cancer Inst 85 1993 365 376
23. D.F. Cella, D.S. Tulsky, and G. Gray The functional assessment of cancer therapy scale: development and validation of the general measure J Clin Oncol 11 1993 570 579
24. W.O. Spitzer, A.J. Dobson, and J. Hall Measuring the quality of life of cancer patients: a concise QL-index for use by physicians J Chronic Dis 34 1981 585 597
25. H. Schipper, J. Clinch, and A. McMurray Measuring the quality of life of cancer patients: the Functional Living Index-Cancer: development and validation J Clin Oncol 2 1984 472 483
26. M.S. Litwin, R.D. Hays, and A. Fink The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure Med Care 36 1998 1002 1012
27. J.T. Wei, R.L. Dunn, and M.S. Litwin Development and validation of the Expanded Prostate Cancer Index Composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer Urology 56 2000 899 905
28. M.R. Stockler, D. Osoba, and P. Corey Convergent discriminitive, and predictive validity of the Prostate Cancer Specific Quality of Life Instrument (PROSQOLI) assessment and comparison with analogous scales from the EORTC QLQ-C30 and a trial-specific module. European Organisation for Research and Treatment of Cancer. Core Quality of Life Questionnaire J Clin Epidemiol 52 1999 653 666
29. W. Dale, T. Campbell, and L. Ignacio Self-assessed health-related quality of life in men being treated for prostate cancer with radiotherapy: instrument validation and its relation to patient-assessed bother of symptoms Urology 53 1999 359 366
30. D.L. Patrick, and R.A. Deyo Generic and disease-specific measures in assessing health status and quality of life Med Care 27 1989 S217 S232
31. J.A. Talcott, J. Manola, and J.A. Clark Time course and predictors of symptoms after primary prostate cancer therapy J Clin Oncol 21 2003 3979 3986
32. J.A. Clark, T.S. Inui, and R.A. Silliman Patients' perceptions of quality of life after treatment for early prostate cancer J Clin Oncol 21 2003 3777 3784
33. P.A. Ganz, C.A. Schag, and J.J. Lee The CARES: a generic measure of health-related quality of life for patients with cancer Qual Life Res 1 1992 19 29
34. K. Akakura, S. Isaka, and S. Akimoto Long-term results of a randomized trial for the treatment of Stages B2 and C prostate cancer: radical prostatectomy versus external beam radiation therapy with a common endocrine therapy in both modalities Urology 54 1999 313 318
35. P. Fransson, J.E. Damber, and R. Tomic Quality of life and symptoms in a randomized trial of radiotherapy versus deferred treatment of localized prostate carcinoma Cancer 92 2001 3111 3119
36. L. Holmberg, A. Bill-Axelson, and F. Helgesen A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer N Engl J Med 347 2002 781 789
37. G. Steineck, F. Helgesen, and J. Adolfsson Quality of life after radical prostatectomy or watchful waiting N Engl J Med 347 2002 790 796
38. A. Auvinen, T. Vornanen, and T.L. Tammela A randomized trial of the choice of treatment in prostate cancer: design and baseline characteristics BJU Int 88 2001 708 715
39. H.J. Rosenberg, S.D. Rosenberg, and M.S. Ernstoff Expressive disclosure and health outcomes in a prostate cancer population Int J Psychiatry Med 32 2002 37 53
40. C.A. McHorney, J.E. Ware, and J.F. Lu The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups Med Care 32 1994 40 66
41. A.S. Zigmond, and R.P. Snaith The hospital anxiety and depression scale Acta Psychiatr Scand 67 1983 361 370
42. J.E. Johansson, P. Wersall, and Y. Brandberg Efficacy of epoetin beta on hemoglobin, quality of life, and transfusion needs in patients with anemia due to hormone-refractory prostate cancer - a randomized study Scand J Urol Nephrol 35 2001 288 294
43. F. Boccardo, A. Rubagotti, and M. Barichello Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study J Clin Oncol 17 1999 2027 2038
44. S.D. Fossa, P.H. Slee, and M. Brausi Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase III study of the European organization for research and treatment of cancer genitourinary group J Clin Oncol 19 2001 62 71
45. S.D. Fossa, D. Curran, and N.K. Aaronson Quality of life of patients with newly diagnosed poor prognosis M1 prostate cancer undergoing orchiectomy without or with mitomycin C. Results from the EORTC Phase-III trial 30893 Eur Urol 37 2000 541 551
46. C.M. Moinpour, M.J. Savage, and A. Troxel Quality of life in advanced prostate cancer: results of a randomized therapeutic trial J Natl Cancer Inst 90 1998 1537 1544
47. L.K. Sharp, S.J. Knight, and R. Nadler Quality of life in low-income patients with metastatic prostate cancer: divergent and convergent validity of three instruments Qual Life Res 8 1999 461 470
48. J.E. Oesterling, S.J. Jacobsen, and C.G. Chute Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges JAMA 270 1993 860 864
49. J.A. Clark, and J.A. Talcott Symptom indexes to assess outcomes of treatment for early prostate cancer Med Care 39 2001 1118 1130
50. B.G. Bokhour, J.A. Clark, and T.S. Inui Sexuality after treatment for early prostate cancer: exploring the meanings of erectile dysfunction J Gen Intern Med 16 2001 649 655
51. J.A. Clark, N. Wray, and B. Brody Dimensions of quality of life expressed by men treated for metastatic prostate cancer Soc Sci Med 45 1997 1299 1309
52. M.S. Litwin, D.J. Pasta, and J. Yu Urinary function and bother after radical prostatectomy or radiation for prostate cancer: a longitudinal, multivariate quality of life analysis from the Cancer of the Prostate Strategic Urologic Research Endeavor J Urol 164 2000 1973 1977
53. M.S. Litwin, S.C. Flanders, and D.J. Pasta Sexual function and bother after radical prostatectomy or radiation for prostate cancer: multivariate quality-of-life analysis from CaPSURE. Cancer of the Prostate Strategic Urologic Research Endeavor Urology 54 1999 503 508
54. C.J. Beard, K.J. Propert, and P.P. Rieker Complications after treatment with external-beam irradiation in early stage prostate cancer patients: a prospective multiinstitutional outcomes study J Clin Oncol 15 1997 223 229
55. P.C. Albertsen, N.K. Aaronson, and M.J. Muller Health-related quality of life among patients with metastatic prostate cancer Urology 49 1997 207 216 discussion 216-217
56. M.S. Litwin, A.I. Shpall, and F. Dorey Quality-of-life outcomes in long-term survivors of advanced prostate cancer Am J Clin Oncol 21 1998 327 332
57. S.P. Kim, C.L. Bennett, and C. Chan QOL and outcomes research in prostate cancer patients with low socioeconomic status Oncology (Huntingt) 13 1999 823 832
58. D.F. Penson, M.L. Stoddard, and D.J. Pasta The association between socioeconomic status, health insurance coverage, and quality of life in men with prostate cancer J Clin Epidemiol 54 2001 350 358
59. J.A. Clark, P. Rieker, and K.J. Propert Changes in quality of life following treatment for early prostate cancer Urology 53 1999 161 168
60. C.G. Bacon, E. Giovannucci, and M. Testa The association of treatment-related symptoms with quality-of-life outcomes for localized prostate carcinoma patients Cancer 94 2002 862 871
61. J.W. Davis, D.A. Kuban, and D.F. Lynch Quality of life after treatment for localized prostate cancer: differences based on treatment modality J Urol 166 2001 947 952
62. D. Curran, S. Fossa, and N. Aaronson Baseline quality of life of patients with advanced prostate cancer. European Organization for Research and Treatment of Cancer (EORTC), genito-urinary tract cancer cooperative group (GUT-CCG) Eur J Cancer 33 1997 1809 1814 E[corrected to Keuppens F]
63. M.V. Tefilli, E.L. Gheiler, and R. Tiguert Quality of life in patients undergoing salvage procedures for locally recurrent prostate cancer J Surg Oncol 69 1998 156 161
64. F. Joly, D. Brune, and J.E. Couette Health-related quality of life and sequelae in patients treated with brachytherapy and external beam irradiation for localized prostate cancer Ann Oncol 9 1998 751 757
65. C.L. Shrader-Bogen, J.L. Kjellberg, and C.P. McPherson Quality of life and treatment outcomes: prostate carcinoma patients' perspectives after prostatectomy or radiation therapy Cancer 79 1997 1977 1986
66. S.D. Fossa, H. Woehre, and K.H. Kurth Influence of urological morbidity on quality of life in patients with prostate cancer Eur Urol 31 Suppl 3 1997 3 8
67. T. Krupski, G.R. Petroni, and E.A. Bissonette Quality-of-life comparison of radical prostatectomy and interstitial brachytherapy in the treatment of clinically localized prostate cancer Urology 55 2000 736 742
68. M.A. Sprangers, A. Cull, and M. Groenvold The European Organization for Research and Treatment of Cancer approach to developing questionnaire modules: an update and overview. EORTC quality of life study group Qual Life Res 7 1998 291 300
69. G. Borghede, and M. Sullivan Measurement of quality of life in localized prostatic cancer patients treated with radiotherapy. Development of a prostate cancer-specific module supplementing the EORTC QLQ-C30 Qual Life Res 5 1996 212 222
70. P. Esper, F. Mo, and G. Chodak Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument Urology 50 1997 920 928
71. J. Ware Jr., M. Kosinski, and S.D. Keller A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity Med Care 34 1996 220 233
72. D.F. Cella, P.B. Jacobsen, and E.J. Orav A brief POMS measure of distress for cancer patients J Chronic Dis 40 1987 939 942
73. G. Kemmler, B. Holzner, and M. Kopp Comparison of two quality-of-life instruments for cancer patients: the functional assessment of cancer therapy-general and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 J Clin Oncol 17 1999 2932 2940
74. H.W. Herr, and M. O'Sullivan Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy J Urol 163 2000 1743 1746
75. P. Stone, J. Hardy, and R. Huddart Fatigue in patients with prostate cancer receiving hormone therapy Eur J Cancer 36 2000 1134 1141
76. U. Monga, A.J. Kerrigan, and J. Thornby Prospective study of fatigue in localized prostate cancer patients undergoing radiotherapy Radiat Oncol Investig 7 1999 178 185
77. J.C. de Haes, F.C. van Knippenberg, and J.P. Neijt Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam Symptom Checklist Br J Cancer 62 1990 1034 1038
78. M.S. Litwin, R.D. Hays, and A. Fink Quality-of-life outcomes in men treated for localized prostate cancer JAMA 273 1995 129 135
79. M.J. Barry, F.J. Fowler Jr., and M.P. O'Leary The American Urological Association symptom index for benign prostatic hyperplasia J Urol 148 1992 1549 1557
80. A. Stewart, and J.E.J. Ware Measuring functioning and well-being: The Medical Outcomes Study approach 1992 Duke University Press Durham, NC
81. M.P. O'Leary, F.J. Fowler, and W.R. Lenderking A brief male sexual function inventory for urology Urology 46 1995 697 706
82. R.C. Rosen, A. Riley, and G. Wagner The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction Urology 49 1997 822 830
83. E.J. Small, M. Meyer, and M.E. Marshall Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone J Clin Oncol 18 2000 1440 1450
84. J.A. Clark, B.G. Bokhour, and T.S. Inui Measuring patients' perceptions of the outcomes of treatment for early prostate cancer Med Care 41 2003 923 936
85. J.A. Talcott, P. Rieker, and J.A. Clark Patient-reported symptoms after primary therapy for early prostate cancer results of a prospective cohort study J Clin Oncol 16 1998 275 283
86. D.P. Lubeck, M.S. Litwin, and J.M. Henning Changes in health-related quality of life in the first year after treatment for prostate cancer: results from CaPSURE Urology 53 1999 180 186
87. P.H. Seo, A.V. D'Amico, and J.A. Clark Assessing a prostate cancer brachytherapy technique using early patient-reported symptoms: a potential early indicator for technology assessment Clin Prostate Cancer 3 2004 38 42
88. Litwin MS, Talcott JA. Quality of life in prostate cancer: past, present, future. In: Lipscomb J, Gotay CC, Snyder C, editors. Outcomes assessment in cancer. Cambridge: Cambridge University Press; 2003 (in press)